Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$9.50 USD
-0.10 (-1.04%)
Updated May 9, 2024 04:00 PM ET
After-Market: $9.49 -0.01 (-0.11%) 5:44 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ORIC 9.50 -0.10(-1.04%)
Will ORIC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ORIC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORIC
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why
ORIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why
Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study
Other News for ORIC
Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)
Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Clinical Data and Strong Financial Position